AKUMS DRUGS & PHARMACEUTICALS
|
|
| BOM : 544222     NSE : AKUMS     | |
| LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
May 27,2026 |
|
Price(EOD): ₹ 535.65
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 8,431.13 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| AKUMS DRUGS & PHARMACEUTICALS | 2.8% | 0.8% | -5.5% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.4% | 6.4% | 7% |
| DIVIS LABORATORIES | -0.9% | 5% | 3.3% |
| TORRENT PHARMACEUTICALS | 1.6% | 7.6% | 38.5% |
| CIPLA | 1.2% | 7.7% | -3.4% |
| DR REDDYS LABORATORIES | 0.1% | -1.2% | 8.7% |
| MANKIND PHARMA | -3.7% | 6.8% | -0.8% |
| LUPIN | -0.4% | -2% | 15% |
| ZYDUS LIFESCIENCES | 4.8% | 16.5% | 19.4% |
FUNDAMENTAL ANALYSIS OF AKUMS DRUGS & PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF AKUMS DRUGS & PHARMACEUTICALS
 | Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
32.88
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 256.40 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] 2.54
P/B Calculated based on Book Value of Rs 3,313.35 Cr
[Latest Year - Mar2026 - Consolidated Results ] 1.93
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 4,359.02 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
582% 818% 4% |
SHARE PRICE MOMENTUM OF AKUMS DRUGS & PHARMACEUTICALS
AKUMS DRUGS & PHARMACEUTICALS vs SENSEX
DEBT OF AKUMS DRUGS & PHARMACEUTICALS
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2025 2024 2023 Avg_3yrs |
0 1.57 0.47 0.68 |
0 0.69 0.75 0.48 |
|
[Last Annual Data : Mar2025]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF AKUMS DRUGS & PHARMACEUTICALS
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2026 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF AKUMS DRUGS & PHARMACEUTICALS
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
-0.15% 3.31% 21.74% 20.2% |
9.69% 61.55% 61.33% -45.63% |
| QtrlyTrend |
4 | |
| Latest Qtr: Mar2026 | ||
| Quarterly Result Analysis → | ||
AKUMS DRUGS & PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 1000 | 1.8% | 1.8% | 0.7% |
| BSE HEALTHCARE | -0.4% | 8.8% | 11.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MICROCAP 250 | 3.5% | 5.6% | 3.3% |
| NIFTY SMALLCAP 500 | 2.8% | NA | NA |
| NIFTY 500 EQUAL WEIGHT | 2.4% | 3.2% | 4.5% |
| NIFTY MIDSMALLCAP400 50:50 | 2.2% | NA | NA |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | 2% | 3.2% | 4.2% |
You may also like the below Video Courses
FAQ about AKUMS DRUGS & PHARMACEUTICALS
Is AKUMS DRUGS & PHARMACEUTICALS good for long term investment?
As on May 27,2026, the Fundamentals of AKUMS DRUGS & PHARMACEUTICALS look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of AKUMS DRUGS & PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is AKUMS DRUGS & PHARMACEUTICALS UnderValued or OverValued?
As on May 27,2026, AKUMS DRUGS & PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of AKUMS DRUGS & PHARMACEUTICALS ?
As on May 27,2026, the Intrinsic Value of AKUMS DRUGS & PHARMACEUTICALS is Rs. 78.56 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 78.56
Fair Value [Median EV / Sales Model] : Rs. 58.37
Fair Value [Median Price / Sales Model] : Rs. 515.92
Estimated Median Fair Value of AKUMS DRUGS & PHARMACEUTICALS : Rs. 78.56
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.